Complete the 12-week Phase 2 VX-548 study in diabetic peripheral neuropathy
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 1 Aug 2023
- Due
- 31 Dec 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Vertex expects to complete this study in late 2023”
What we found
Evidence strength A What the grades mean
Filings state the Phase 2 VX-548 diabetic peripheral neuropathy trial was completed and positive results were announced in December 2023, within the late-2023 deadline.
-
A Vertex Pharmaceuticals 8-K filed 2024-02-05
“In December 2023, Vertex shared positive Phase 2 results with VX-548 in diabetic peripheral neuropathy” ✓ confirmed on the page
-
A Vertex Pharmaceuticals 10-K filed 2024-02-15
“We have completed the Phase 2 dose-ranging clinical trial evaluating VX-548 in patients with diabetic peripheral neuropathy” ✓ confirmed on the page
-
A Vertex Pharmaceuticals 10-K filed 2024-02-15
“in December 2023, we announced results from a Phase 2 clinical trial evaluating VX-548 in people with DPN” ✓ confirmed on the page
Market reaction: the shares moved -2.1% against the S&P 500 over the three sessions around the disclosure (2 Feb 2024 to 7 Feb 2024). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- 12-week Phase 2 VX-548 study completion
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Vertex Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-VRTX-006529 · Corrections policy